Drug
OF Tqh2722
OF Tqh2722: highest development phase Phase 2, developed by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| 300mg of TQH2722 injection NCT06089278 | Phase 2 | Sinusitis |
Latest
No recent events.
Follow OF Tqh2722 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.